285 related articles for article (PubMed ID: 26681486)
21. Evaluation of the Risk of Relapse in Ulcerative Colitis According to the Degree of Mucosal Healing (Mayo 0 vs 1): A Longitudinal Cohort Study.
Barreiro-de Acosta M; Vallejo N; de la Iglesia D; Uribarri L; Bastón I; Ferreiro-Iglesias R; Lorenzo A; Domínguez-Muñoz JE
J Crohns Colitis; 2016 Jan; 10(1):13-9. PubMed ID: 26351390
[TBL] [Abstract][Full Text] [Related]
22. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis.
Brandse JF; van den Brink GR; Wildenberg ME; van der Kleij D; Rispens T; Jansen JM; Mathôt RA; Ponsioen CY; Löwenberg M; D'Haens GR
Gastroenterology; 2015 Aug; 149(2):350-5.e2. PubMed ID: 25917786
[TBL] [Abstract][Full Text] [Related]
23. Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis.
Fernández-Blanco JI; Fernández-Díaz G; Cara C; Vera MI; Olivares D; Taxonera C
Dig Dis Sci; 2018 Mar; 63(3):731-737. PubMed ID: 29372480
[TBL] [Abstract][Full Text] [Related]
24. Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab.
Magro F; Lopes SI; Lopes J; Portela F; Cotter J; Lopes S; Moreira MJ; Lago P; Peixe P; Albuquerque A; Rodrigues S; Silva MR; Monteiro P; Lopes C; Monteiro L; Macedo G; Veloso L; Camila C; Afonso J; Geboes K; Carneiro F;
J Crohns Colitis; 2016 Dec; 10(12):1407-1416. PubMed ID: 27226417
[TBL] [Abstract][Full Text] [Related]
25. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis.
Kobayashi T; Suzuki Y; Motoya S; Hirai F; Ogata H; Ito H; Sato N; Ozaki K; Watanabe M; Hibi T
J Gastroenterol; 2016 Mar; 51(3):241-51. PubMed ID: 26162647
[TBL] [Abstract][Full Text] [Related]
26. Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis.
Olsen T; Rismo R; Gundersen MD; Paulssen EJ; Johnsen K; Kvamme JM; Goll R; Florholmen J
Cytokine; 2016 Mar; 79():90-5. PubMed ID: 26775117
[TBL] [Abstract][Full Text] [Related]
27. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
Roblin X; Marotte H; Rinaudo M; Del Tedesco E; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
Clin Gastroenterol Hepatol; 2014 Jan; 12(1):80-84.e2. PubMed ID: 23891927
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: a retrospective multicenter French experience.
Filippi J; Laharie D; Michiels C; Flamand M; Bouguen G; Nancey S; Presles E; Paul S; Schneider S; Hébuterne X; Roblin X
J Crohns Colitis; 2015 Mar; 9(3):252-8. PubMed ID: 25588386
[TBL] [Abstract][Full Text] [Related]
29. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis.
Olsen T; Goll R; Cui G; Christiansen I; Florholmen J
Cytokine; 2009 May; 46(2):222-7. PubMed ID: 19286392
[TBL] [Abstract][Full Text] [Related]
30. Tacrolimus for remission induction in ulcerative colitis: Mayo endoscopic subscore 0 and 1 predict long-term prognosis.
Ikeya K; Sugimoto K; Kawasaki S; Iida T; Maruyama Y; Watanabe F; Hanai H
Dig Liver Dis; 2015 May; 47(5):365-71. PubMed ID: 25682993
[TBL] [Abstract][Full Text] [Related]
31. Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes.
Christensen B; Hanauer SB; Erlich J; Kassim O; Gibson PR; Turner JR; Hart J; Rubin DT
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1557-1564.e1. PubMed ID: 28238954
[TBL] [Abstract][Full Text] [Related]
32. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience.
Laharie D; Filippi J; Roblin X; Nancey S; Chevaux JB; Hébuterne X; Flourié B; Capdepont M; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2013 May; 37(10):998-1004. PubMed ID: 23521659
[TBL] [Abstract][Full Text] [Related]
33. Intensified Infliximab Induction is Associated with Improved Response and Decreased Colectomy in Steroid-Refractory Paediatric Ulcerative Colitis.
Church PC; Ho S; Sharma A; Tomalty D; Frost K; Muise A; Walters TD; Griffiths AM
J Crohns Colitis; 2019 Aug; 13(8):982-989. PubMed ID: 30715240
[TBL] [Abstract][Full Text] [Related]
34. Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis.
Mei WQ; Hu HZ; Liu Y; Li ZC; Wang WG
World J Gastroenterol; 2015 May; 21(19):6044-51. PubMed ID: 26019471
[TBL] [Abstract][Full Text] [Related]
35. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study.
Lee KM; Jeen YT; Cho JY; Lee CK; Koo JS; Park DI; Im JP; Park SJ; Kim YS; Kim TO; Lee SH; Jang BI; Kim JW; Park YS; Kim ES; Choi CH; Kim HJ;
J Gastroenterol Hepatol; 2013 Dec; 28(12):1829-33. PubMed ID: 23829336
[TBL] [Abstract][Full Text] [Related]
36. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy.
De Vos M; Louis EJ; Jahnsen J; Vandervoort JG; Noman M; Dewit O; Dʼhaens GR; Franchimont D; Baert FJ; Torp RA; Henriksen M; Potvin PM; Van Hootegem PP; Hindryckx PM; Moreels TG; Collard A; Karlsen LN; Kittang E; Lambrecht G; Grimstad T; Koch J; Lygren I; Coche JC; Mana F; Van Gossum A; Belaiche J; Cool MR; Fontaine F; Maisin JM; Muls V; Neuville B; Staessen DA; Van Assche GA; de Lange T; Solberg IC; Vander Cruyssen BJ; Vermeire SA
Inflamm Bowel Dis; 2013 Sep; 19(10):2111-7. PubMed ID: 23883959
[TBL] [Abstract][Full Text] [Related]
37. Assessment of induction therapy with infliximab in children with moderate to severe ulcerative colitis: a multi-center study.
Szychta M; Wiernicka A; Dądalski M; Landowski P; Klincewicz B; Karolewska-Bochenek K; Czaja-Bulsa G; Jarocka-Cyrta E; Korczowski B; Sladek M; Kierkus J
Dev Period Med; 2016; 20(3):205-211. PubMed ID: 27941190
[TBL] [Abstract][Full Text] [Related]
38. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
Cholapranee A; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
Aliment Pharmacol Ther; 2017 May; 45(10):1291-1302. PubMed ID: 28326566
[TBL] [Abstract][Full Text] [Related]
39. The Ulcerative Colitis Response Index for Detection of Mucosal Healing in Patients Treated With Anti-tumour Necrosis Factor.
de Bruyn M; Ringold R; Martens E; Ferrante M; Van Assche G; Opdenakker G; Dukler A; Vermeire S
J Crohns Colitis; 2020 Feb; 14(2):176-184. PubMed ID: 31628842
[TBL] [Abstract][Full Text] [Related]
40. Mucosal Healing in Ulcerative Colitis--When Zero is Better.
Boal Carvalho P; Dias de Castro F; Rosa B; Moreira MJ; Cotter J
J Crohns Colitis; 2016 Jan; 10(1):20-5. PubMed ID: 26438714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
